Study Phase 3

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Trial Information

Generic NameAd26.COV2.SProduct NameJanssen COVID-19 VaccineTherapeutic AreaAnti-Infectives for Systemic UseProduct ClassVaccinesPharmacological SubgroupViral VaccinesChemical SubgroupCOVID-19 VaccinesCondition StudiedCoronavirus Disease
Sponsor Protocol NumberVAC31518COV3001Enrollment44325Data PartnerJohnson & Johnson% Female45.1%Mean/Median Age (Years)50.3% White58.7%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.